Prostate Cancer Screening in Men With Germline BRCA2 Mutations

This is a cohort screening study to prospectively identify the incidence of prostate cancer
in a population of BRCA2 carriers. All men identified to have a BRCA2 mutation as part of the
Yale Cancer Genetic Counseling Program will be approached and offered participation in the
study via our program newsletter, BRCA listserv, Facebook page and a targeted mailing.

Standard of care screening at the Yale Cancer Center for men with a normal prostate cancer
risk consists of a PSA test and prostate physical examination beginning at age 50 years and
if either is abnormal an MRI of the prostate followed by Fusion-targeted biopsy of the
prostate is performed.

Inclusion Criteria:

- All men ≥30 years of age with at least a ten-year life expectancy

- A known BRCA2 mutation

- Ability to have an MRI

- Able to give informed consent will be approached to participate in the study

Exclusion Criteria:

- If a man has received or is currently receiving treatment for prostate cancer